Dr. Amanda Nizam

So I tell patients up front, you will get this at some point.

It is a cumulative toxicity with time.

But if we're proactive about dose reductions, people can stay on treatment for much longer and still maintain their efficacy.

We've seen that data from Dan Petralak at ASCO 2024.

that, you know, those patients who did get full dose in the first two cycles and still had subsequent dose reduction still maintained their efficacy in response.

We saw that from Shilpa Gupta's data at ASCO 2025, and the responders, patients who were responding were able to stay on therapy longer with, you know, proactive dose reduction.

So that's

extremely important, especially because neuropathy is the most common dose-limiting toxicity.

We also saw that in Unite in the paper we published in October.

So if you're really proactive about this, people can derive benefit longer without getting to this quality of life-limiting toxicity.

And that's especially important as we're talking about sequencing of other agents that still use the vedotin payload because we're seeing a lot of trials right now that are using vedotin payloads.

And neuropathy is the most common with those payloads.

So we have to be very careful in terms of thinking of sequencing and cumulative toxicities.

Yeah.

So the initial data that Matt Galske presented from the phase two, the RC48G001, I think that was at ESMO 2024, that I think most patients were HER2 low, like 14 patients, and then HER2 positive, there were six patients.

But the data looks pretty promising.

And now we're waiting the phase three, which is enrolling globally.

And we'll see.

And as you mentioned, the DV to our Palomam trial in China, that was one plus, two plus, three plus.

And that was obviously a very, very impressive response rate.